A scoring system tool that incorporates both CYP2C19 activity on a continuous scale, together with the inhibitory effect of DDIs and comorbidities (i.e., liver disease) will likely improve the pharmaco-genotype to phenotype translation. The gene discussed is CYP2C19; the disease is liver disorder.